Showing results (21-30 of 46) with videos related to
Sort By:
Pageof 5
Future Oncology (London, England)|June 6, 2025
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosisLucia Masarova, Srdan Verstovsek, Francesca Palandri, et al.Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|March 21, 2006
Survival of patients with ALS following institution of enteral feeding is related to pre-procedure oximetry: a retrospective review of 98 patients in a single centreAshley S Shaw, Mary-Ann Ampong, Alan Rio, et al.European Journal of Haematology|July 15, 2026
Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY-1 and MOMENTUM TrialsFrancesca Palandri, Casey O'Connell, Pankit Vachhani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancerKimberly L Blackwell, Harold J Burstein, Anna Maria Storniolo, et al.JAMA Oncology|June 10, 2016
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without LapatinibAleix Prat, Maggie C U Cheang, Patricia Galván, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2012
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 StudyKimberly L Blackwell, Harold J Burstein, Anna Maria Storniolo, et al.Advances in Therapy|July 11, 2024
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2Claire N Harrison, Alessandro M Vannucchi, Christian Recher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast CancerChee Khoon Lee, Lucy Davies, Val J Gebski, et al.The Oncologist|August 7, 2015
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast CancerValentina Guarneri, Maria Vittoria Dieci, Antonio Frassoldati, et al.Journal of Neurochemistry|February 27, 2003
Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelinAndrew D Medhurst, Carol A Jennings, Melanie J Robbins, et al.Pageof 5